Salivary biomarkers in COVID-19 patients.

The use of salivary biomarkers in diagnosis, treatment, and overall prognosis of coronavirus disease 2019 (COVID-19) has been developed recently. Salivary biomarkers are extremely promising as they are fast to obtain and involve noninvasive collection of specimens. Monitoring patients in real time is necessary in this pandemic. Saliva is another biofluid with major advantages at the molecular level. Methods that detect viral presence in the host secretions measure the current infection by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), whereas the detection of human antibodies against SARS-CoV-2 evaluates the past exposure to the virus. There is an urgent need to increase the active research for the detection of SARS-CoV-2 in saliva because diagnostics may provide a reliable and cost-effective method and is suitable for the fast and early detection of COVID-19 infection. Salivary biomarkers have a potential to be a vital guide in determining coronavirus disease. Many people still do not get results of COVID-19 tests due to imbalance between supply and demand at large testing centers. The use of saliva has various advantages compared to collection of nasopharyngeal swabs. New techniques should be developed for detecting salivary biomarkers that help in diagnosis of COVID-19.